78 related articles for article (PubMed ID: 8954966)
1. Inhibitors of Ras farnesylation revert the increased resistance to oxidative stress in K-Ras transformed NIH 3T3 cells.
Santillo M; Mondola P; Gioielli A; Serù R; Iossa S; Annella T; Vitale M; Bifulco M
Biochem Biophys Res Commun; 1996 Dec; 229(3):739-45. PubMed ID: 8954966
[TBL] [Abstract][Full Text] [Related]
2. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cell growth by lovastatin is independent of ras function.
DeClue JE; Vass WC; Papageorge AG; Lowy DR; Willumsen BM
Cancer Res; 1991 Jan; 51(2):712-7. PubMed ID: 1985788
[TBL] [Abstract][Full Text] [Related]
4. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
Aklilu F; Park M; Goltzman D; Rabbani SA
Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
[TBL] [Abstract][Full Text] [Related]
5. Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin.
Chuang JI; Chang TY; Liu HS
Oncogene; 2003 Mar; 22(9):1349-57. PubMed ID: 12618760
[TBL] [Abstract][Full Text] [Related]
6. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
7. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC
Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355
[TBL] [Abstract][Full Text] [Related]
9. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation.
Recktenwald CV; Kellner R; Lichtenfels R; Seliger B
Cancer Res; 2008 Dec; 68(24):10086-93. PubMed ID: 19074874
[TBL] [Abstract][Full Text] [Related]
10. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation.
Wang IK; Lin-Shiau SY; Lin JK
Oncology; 2000 Sep; 59(3):245-54. PubMed ID: 11053993
[TBL] [Abstract][Full Text] [Related]
11. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity.
McGuire TF; Sebti SM
Oncogene; 1997 Jan; 14(3):305-12. PubMed ID: 9018116
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state.
Laezza C; Fiorentino L; Pisanti S; Gazzerro P; Caraglia M; Portella G; Vitale M; Bifulco M
J Mol Med (Berl); 2008 Dec; 86(12):1341-51. PubMed ID: 18779944
[TBL] [Abstract][Full Text] [Related]
14. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
Cuthbert JA; Lipsky PE
Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
[TBL] [Abstract][Full Text] [Related]
15. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.
Tolsma SS; Cohen JD; Ehrlich LS; Bouck NP
Exp Cell Res; 1993 Apr; 205(2):232-9. PubMed ID: 8482334
[TBL] [Abstract][Full Text] [Related]
16. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin blocks N-ras oncogene-induced neuronal differentiation.
Mendola CE; Backer JM
Cell Growth Differ; 1990 Oct; 1(10):499-502. PubMed ID: 2278880
[TBL] [Abstract][Full Text] [Related]
19. Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin.
Chang MY; Jan MS; Won SJ; Liu HS
Biochem Biophys Res Commun; 1998 Jul; 248(1):62-8. PubMed ID: 9675086
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
